Impact of high-pressure/high-dose pressurized intraperitoneal aerosol chemotherapy (HP/HD PIPAC) on perioperative outcome and overall survival in patients with advanced peritoneal carcinomatosis

Recruiting

• Conditions: C78.6; C18; C19; C20; Secondary malignant neoplasm of retroperitoneum and peritoneum; Malignant neoplasm of colon; Malignant neoplasm of rectosigmoid junction; Malignant neoplasm of rectum

• Registration Number: DRKS00032990
• Lead Sponsor: Klinikum Dortmund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

Patients who underwent surgery for PIPAC because of peritoneal carcinomatosis

Exclusion Criteria

Patients who objected to retrospective data analysis

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is mortality after PIPAC therapy. This is determined by a one-time query from relatives, other medical practitioners or the residents' registration office.

Secondary Outcome Measures

Name	Time	Method
Perioperative outcome with complications and morbidity is recorded retrospectively once based on the treatment files.